Vigilant Biosciences roped in $5.5 million in a Series B round to support development of its diagnostic system for the early detection of oral cancer, giving the company a boost as it eyes European and stateside approval for its product.
Pakistan's minister in charge of drug pricing confirmed at a news conference a new policy would reduce the costs of some drugs by as much as 30%, but said no changes would become effective before June 30, 2016.
Taiwan-based ACT Genomics raked in $8 million in the company's first private funding round, giving the company a boost as it looks to ramp up development for its molecular diagnostic cancer assays.
The board of directors at GlaxoSmithKline voted to approve the last phase of a three-part deal with Novartis, transferring GSK's cancer drug portfolio to Novartis Healthcare Pvt, its Indian arm. Distribution rights were ceded in exchange for acquiring the Swiss-based company's vaccines portfolio.
Guardant Health used the occasion of a $50 million investment to declare its leadership in the still-developing business of liquid biopsies. That brings the total raised to just under $100 million. The latest cash infusion is intended to expand marketing of its Guardant360 product and to improve upon it.
Researchers at Florida's Moffitt Cancer Center are gaining deeper insight into the biological processes going on inside a tumor in an effort to battle cancer more effectively. They've developed a new technique to analyze specific protein complexes in cancer specimens.
Philips announced that it will offer Indica Lab's Halo image analysis software platform with its Digital Pathology Solutions products to enable enhanced analysis of cancerous tissue samples. The upgraded product offering is for research use only, meaning it won't be used to make clinical decisions affecting individual patients.
Famed biotech entrepreneur Dr. Patrick Soon-Shiong opted to unveil core details on his patient monitoring company NantHealth at this week's JP Morgan Healthcare conference. The private company has already spent $1.5 billion in the past decade to enable patient monitoring and real-time data analysis that examines the patient experience in the hospital and at home via connected medical devices, as well as to cost and outcomes data that's available via mobile devices.
Researchers have developed graphene strips that have demonstrated the ability to carry two different cancer drugs and target each to the part of the cell where it will be most effective. The surface area of a flat strip in particular suits these particles to the delivery of the cancer drugs TRAIL and doxorubicin.
Cerulean Pharma announced last week that the first patient has received its Phase I/IIa cancer candidate, CRLX301, delivered using its RNA-based Dynamic Tumor Targeting Platform.